Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Jul;35(7):1321–1328. doi: 10.1128/aac.35.7.1321

Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis.

T J Walsh 1, J W Lee 1, P Kelly 1, J Bacher 1, J Lecciones 1, V Thomas 1, C Lyman 1, D Coleman 1, R Gordee 1, P A Pizzo 1
PMCID: PMC245165  PMID: 1929288

Abstract

Cilofungin (LY-121019) is a fungicidal cell wall-active 1,3-beta-glucan synthetase inhibitor with a short plasma half-life and saturable nonlinear plasma pharmacokinetics. To optimize the in vivo efficacy of this compound, we studied the effects of its linear and nonlinear pharmacokinetics during continuous versus intermittent intravenous infusion of cilofungin in the treatment of experimental disseminated candidiasis in persistently granulocytopenic rabbits. Six groups of rabbits were studied, untreated controls (n = 32) and five cilofungin dosage regimen groups consisting of the following: 25 mg/kg of body weight intravenously twice daily (VLoINT) (n = 9); 50 mg/kg twice daily (LoINT) (n = 9); 90 mg/kg twice daily (HiINT) (n = 11); 5 mg/kg/h for 18 h/day (LoCI) (n = 7); and 10 mg/kg/h for 18 h/day (HiCI) (n = 7). All regimens achieved plasma concentrations exceeding the MIC for Candida albicans (0.25 microgram/ml). In vitro timed kill assays found that the fungicidal activity and rate of kill by cilofungin above the MIC for C. albicans was concentration dependent. At the lower dosage regimens (VLoINT, LoINT, and LoCI), cilofungin followed linear plasma pharmacokinetics, whereas at higher doses (HiCI and HiINT), nonlinear kinetics consistent with a saturated elimination pathway(s) were observed. Only HiCI and HiINT produced a 10(3)- to 10(4)-fold reduction in CFU per gram in candidiasis of the brain (P less than or equal to 0.001). HiCI and HiINT also significantly reduced infection in the choroid (P less than or equal to 0.05). All regimens, except VLoInt, significantly (P less than or equal to 0.01) reduced tissue infections in lung, liver, spleen, and kidney. However, only the regimens with nonlinear saturation kinetics (HiCI and HiINT) produced a 10(6) reduction in the spleen and a > 10(5) reduction of C. albicans in the kidney and liver. A simple doubling of the dosage from LoCI to HiCI resulted in tissue concentrations that were 10 times higher and a 10(2)- to 10(4)-fold-greater antifungal effect. There was a direct correlation (r2 = 0.83) between tissue concentrations of cilofungin and antifungal activity. Thus, continuous and intermittent infusion dosage regimens that elicit nonlinear saturation plasma pharmacokinetics of cilofungin were associated with increased antifungal activity against experimental disseminated candidiasis.

Full text

PDF
1322

Images in this article

1325Image
on p.1325
1326Image
on p.1326

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Becker J. M., Marcus S., Tallock J., Miller D., Krainer E., Khare R. K., Naider F. Use of the chitin-synthesis inhibitor nikkomycin to treat disseminated candidiasis in mice. J Infect Dis. 1988 Jan;157(1):212–214. doi: 10.1093/infdis/157.1.212. [DOI] [PubMed] [Google Scholar]
  2. Cassone A. Cell wall of pathogenic yeasts and implications for antimycotic therapy. Drugs Exp Clin Res. 1986;12(6-7):635–643. [PubMed] [Google Scholar]
  3. Cole G. T., Lynn K. T., Seshan K. R. Evaluation of a murine model of hepatic candidiasis. J Clin Microbiol. 1990 Aug;28(8):1828–1841. doi: 10.1128/jcm.28.8.1828-1841.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Debono M., Abbott B. J., Turner J. R., Howard L. C., Gordee R. S., Hunt A. S., Barnhart M., Molloy R. M., Willard K. E., Fukuda D. Synthesis and evaluation of LY121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B. Ann N Y Acad Sci. 1988;544:152–167. doi: 10.1111/j.1749-6632.1988.tb40398.x. [DOI] [PubMed] [Google Scholar]
  5. Edman J. C., Kovacs J. A., Masur H., Santi D. V., Elwood H. J., Sogin M. L. Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature. 1988 Aug 11;334(6182):519–522. doi: 10.1038/334519a0. [DOI] [PubMed] [Google Scholar]
  6. Fromtling R. A., Abruzzo G. K. L-671,329, a new antifungal agent. III. In vitro activity, toxicity and efficacy in comparison to aculeacin. J Antibiot (Tokyo) 1989 Feb;42(2):174–178. doi: 10.7164/antibiotics.42.174. [DOI] [PubMed] [Google Scholar]
  7. Gordee R. S., Zeckner D. J., Ellis L. F., Thakkar A. L., Howard L. C. In vitro and in vivo anti-Candida activity and toxicology of LY121019. J Antibiot (Tokyo) 1984 Sep;37(9):1054–1065. doi: 10.7164/antibiotics.37.1054. [DOI] [PubMed] [Google Scholar]
  8. Gordee R. S., Zeckner D. J., Howard L. C., Alborn W. E., Jr, Debono M. Anti-Candida activity and toxicology of LY121019, a novel semisynthetic polypeptide antifungal antibiotic. Ann N Y Acad Sci. 1988;544:294–309. doi: 10.1111/j.1749-6632.1988.tb40415.x. [DOI] [PubMed] [Google Scholar]
  9. Hobbs M., Perfect J., Durack D. Evaluation of in vitro antifungal activity of LY121019. Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):77–80. doi: 10.1007/BF01962182. [DOI] [PubMed] [Google Scholar]
  10. Lee J. W., Kelly P., Lecciones J., Coleman D., Gordee R., Pizzo P. A., Walsh T. J. Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits. Antimicrob Agents Chemother. 1990 Nov;34(11):2240–2245. doi: 10.1128/aac.34.11.2240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Melchinger W., Müller J. Studies on the in vitro-sensitivity of yeast strains isolated from clinical specimens to LY 121019, a new antifungal agent. Mykosen. 1987 Dec;30(12):605–608. doi: 10.1111/j.1439-0507.1987.tb04383.x. [DOI] [PubMed] [Google Scholar]
  12. Odds F. C. Activity of cilofungin (LY121019) against Candida species in vitro. J Antimicrob Chemother. 1988 Dec;22(6):891–897. doi: 10.1093/jac/22.6.891. [DOI] [PubMed] [Google Scholar]
  13. Padula A., Chambers H. F. Evaluation of cilofungin (LY121019) for treatment of experimental Candida albicans endocarditis in rabbits. Antimicrob Agents Chemother. 1989 Oct;33(10):1822–1823. doi: 10.1128/aac.33.10.1822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Perfect J. R., Hobbs M. M., Wright K. A., Durack D. T. Treatment of experimental disseminated candidiasis with cilofungin. Antimicrob Agents Chemother. 1989 Oct;33(10):1811–1812. doi: 10.1128/aac.33.10.1811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pfaller M. A., Wey S., Gerarden T., Houston A., Wenzel R. P. Susceptibility of nosocomial isolates of Candida species to LY121019 and other antifungal agents. Diagn Microbiol Infect Dis. 1989 Jan-Feb;12(1):1–4. doi: 10.1016/0732-8893(89)90035-7. [DOI] [PubMed] [Google Scholar]
  16. Schmatz D. M., Romancheck M. A., Pittarelli L. A., Schwartz R. E., Fromtling R. A., Nollstadt K. H., Vanmiddlesworth F. L., Wilson K. E., Turner M. J. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5950–5954. doi: 10.1073/pnas.87.15.5950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Spitzer E. D., Travis S. J., Kobayashi G. S. Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis. 1988 Feb;7(1):80–81. doi: 10.1007/BF01962183. [DOI] [PubMed] [Google Scholar]
  18. Taft C. S., Selitrennikoff C. P. LY121019 inhibits Neurospora crassa growth and (1-3)-beta-D-glucan synthase. J Antibiot (Tokyo) 1988 May;41(5):697–701. doi: 10.7164/antibiotics.41.697. [DOI] [PubMed] [Google Scholar]
  19. Walsh T. J., Bacher J., Pizzo P. A. Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci. 1988 Aug;38(4):467–471. [PubMed] [Google Scholar]
  20. Walsh T. J., McEntee C., Dixon D. M. Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans. J Clin Microbiol. 1987 May;25(5):931–932. doi: 10.1128/jcm.25.5.931-932.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES